Stemcell Companies Market

Industry Insights-

• The Global Stemcell Companies Market was valued at USD 154.05 Million in 2022
• It is anticipated to reach USD 330.05 Million by 2029
• A CAGR of 11.5% is anticipated over the forecast period

Overview-

The top stem cell companies are working hard to make advances in therapies. A stem cell is a cell which used to develop into specialized cell types in the body. In the life sciences sector, stem cell research and regenerative medicine are growing markets. Stem cells are special human cells which are able to develop into many different cell types. Stem cells are the building blocks of life, with special capabilities that are used in both the early and later stages of a human’s life cycle. In the future, stem cell may be used to replace cells and tissues that have been damaged or lost due to disease.

Covid-19 Impact-

The COVID-19 pandemic has had a positive impact on the market for stem cells. As medical researchers increase their interest in the study of the novel coronavirus and its treatments, clinical trials have become more common. Regenerative medicine based on cellular therapy is being explored as a potential treatment option for patients, which could lead to a decrease in mortality and infection rates. Companies and research institutes are joining forces to create new treatments for the disease, such as the Infectious Disease Research Institute and Celularity, who announced in April 2020 that the US FDA had approved a clinical trial application to develop cell-based therapy for COVID-19. This increased demand for stem cells in clinical trials is expected to drive the market during the forecast period.

Key Players-

Some of the key players for global Stemcell Companies Market are-

• Becton Dickinson and Company
• Bio-Rad Laboratories
• Miltenyi Biotec
• Takara Bio Group
• STEMCELL Technologies
• Thermo Fisher Scientific
• Merck Group
• Anterogen
• Cellular Dynamics International
• MEDIPOST
• Lonza Group
• Holostem Terapie Avanzate
• Pharmicell
• Osiris Therapeutics
• Amgen
• Sanofi
• Gilead Sciences
• Vertex Pharmaceuticals
• Moderna
• others

Segmentation Analysis-

By Product:

• Stem Cell Lines

  • Embryonic Stem Cells (ESCs)
  • Hemopoietic Stem Cells (HSCs)
  • Mesenchymal Stem Cells (MSCs)
  • Multipotent Adult Progenitor Stem Cells
  • Induced Pluripotent Stem Cells (iPSCs)
  • Neural Stem Cells (NSCs)

• Instruments

  • Bioreactors & Incubators
  • Cell Sorters
  • Other Instruments
• Culture Media
• Consumables

By Application:

• Research Applications

  • Drug Discovery & Development
  • Life Science Research

• Clinical Applications

  • Autologous Stem Cells
  • Allogeneic Stem Cells
• Cell and Tissue Banking Applications

By End-User:

• Hospitals and Surgical Centers
• Pharmaceutical and Biotech Companies
• Cell Banks and Tissue Banks
• Academic Institutes, Research Laboratories, and CROs
• Other End Users

The global stemcell companies market is segmented on the basis of product, application, end-user and by regional & country level. Based on product, global stemcell companies market is classified into stem cell lines, instruments, culture media and consumables. Based upon stem cell lines, the market is sub-classified into embryonic stem cells (ESCs), hemopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), multipotent adult progenitor stem cells, induced pluripotent stem cells (iPSCs) and neural stem cells (NSCs).

Based upon instruments, global stemcell companies market is sub-classified into bioreactors & incubators, cell sorters and other instruments. Based upon application, global stemcell companies market is classified into research applications, clinical applications and cell and tissue banking applications. Based upon research applications, global stemcell companies market is sub-classified into drug discovery & development and life science research. Based upon Clinical applications, global stemcell companies market is sub-classified into autologous stem cells and allogeneic stem cells. Based upon end-user, global stemcell companies market is classified into hospitals and surgical centers, pharmaceutical and biotech companies, cell banks and tissue banks, academic institutes, research laboratories, and CROs and other end users.

By Regional & Country Analysis:

• North America

  • US.
  • Mexico
  • Canada

• Europe

  • UK
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• South America

  • Brazil,
  • Argentina
  • Columbia

• The Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa.

North America is expected to dominate the global stemcell companies market with highest market share due to the high intensity of stem cell research, rising public-private funding to support the clinical evaluation of stem cells for various applications and rising awareness among the people about advanced treatment for cancers in this region. According to National Cancer Institute’s data report, in the United States, about 414,773 people living with leukemia in 2016. Cancer is one among the leading causes of death and disease within the U.S. In addition, favorable government initiatives and presence of major biotechnology companies are also fostering the market growth in this region.

Asia Pacific stemcell companies market is expected to witness a strong growth majorly due to the high population growth rate, increasing government initiatives regarding awareness in peoples about stem cell banking and  growing prevalence of cardiac diseases, cancers etc. in this region. According to leukemia study report, India has the third highest number of blood cancer patients in the world after the US and China. Blood cancer contributes to 7% of all cancer cases in India. According to report by United Nations, 61% of the global population lives in Asia (4.7 billion).

For example, Cord Blood Foundation, provides family cord blood banking means parents pay a private bank to store their baby’s cord blood so that in case of need they will have access to the stem cells for the treatment. In addition, strong product pipelines in cell-based therapies and rising adoption of advanced technologies in emerging countries like Japan, India and China are also supplementing the market growth in this region. For example, HEALIOS K.K. is a Japan-based pharmaceutical company. It is one of the first companies to test the iPS-based treatment in the country.

Market Drivers-

Rising incidences of blood cancer as well as chronic and genetic diseases

Rising incidences of blood cancer, chronic and genetic diseases, and availability of advanced healthcare infrastructure, improved patient outcomes and growing public awareness about the therapeutic potency of stem cell products are the major factors driving the growth of the global stemcell companies market. According to Leukemia Research Foundation, more than 175,000 new cases of blood cancer were diagnosed in the United States in 2019. As per National Institutes of Health, in the United States, about 1 in 200,000 people is born with syndrome A per year and An estimated 12,000 people died from syndrome C worldwide in 2015.

Increasing initiatives for research collaboration and the advancement in cancer research

The increasing initiatives for research collaboration, the advancement in cancer research and more patients with cancer are being successfully treated are majorly responsible for the continuous growth of the global stemcell companies market. For example, in 2019, Evotec SE announced the collaboration expansion with Celgene to include a new iPSC. The collaboration followed an innovative approach towards discovering disease-modifying treatments for patients suffering from neurodegenerative diseases by leveraging Evotec's unique human iPSC technology platform, which is one of the largest and most sophisticated platforms in the industry. However, high costs associated with stem cell manufacturing & banking is may hamper the growth of global stemcell companies market. In spite of that, technological advancements in stem cell-based research may create more opportunities for the further growth of the stemcell companies market.

Recent Developments-

• January 4th, 2019; Cesca Therapeutics completed the acquisition of ThermoGenesis Corp., making it the wholly-owned subsidiary of the Cesca Therapeutics and focused at developing and commercializing automated technologies and medical devices incorporated in the therapies. Also, this acquisition will focus on the manufacturing CAR-T cell therapies for cancer using the automated CAR-TXpress system.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2022:	USD 154.05 Million
Base year considered	2021
Forecast Period CAGR %:	11.5%
Market Size Expected in 2029:	USD 330.05 Million
Tables, Charts & Figures:	175
Pages	300
Players	FirstLight Technologies Ltd., Enaqua, Severn Trent Plc, Xylem Inc., Trojan Technologies, Aquionics, Green Water Technologies, Advanced UV, Inc., Hydro, Photon Technologies, SteriPEN, Calgon Carbon Corporation, General Lighting, Trojan Technologies., Halma PLC. ,Calgon Carbon Corporation. ,Atlantic Ultraviolet Corporation, Evoqua Water Technologies LLC. ,American Ultraviolet , Dr. Honle AG, Atlantium Technologies LTD., Xenex, Lumalier Corporation, Sita Srl, Hitech Ultraviolet Pvt. Ltd. And Others.
Segments Covered	By Component, By Application, By End-User
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa